Contingency Management Using Smartphone App in Patients With SUD
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04162132 |
Recruitment Status :
Completed
First Posted : November 14, 2019
Last Update Posted : November 20, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Substance Use Disorders | Device: Smartphone app |
The purpose of this research study was to test the acceptance and efficacy of a smartphone app (DynamiCare Rewards) for patients with substance use disorder (SUD) who are in active treatment and recovery at BrightView (www.brightviewhealth.com). Patients performed self-tracking of their recovery behavior (e.g., counseling attendance, abstinence from drugs and alcohol) addiction recovery behavior using the DynamiCare app, which follows Contingency Management (CM) model of incentivizing positive behavior.
CM is shown as a highly effective, evidence-based methodology for improving substance use disorder (SUD) outcomes. It does so by activating the brain's reward and inhibitory systems through both positive and negative reinforcement using immediate, concrete incentives in a progressive reinforcement schedule. CM involves setting frequent (>1/week), objective goals (usually abstinence or participation in treatment), which patients can achieve to earn tangible rewards (such as cash or vouchers). The DynamiCare smart phone app (iOS/Android) uses CM to incentivize patients to attend scheduled appointments and to submit negative alcohol and drug tests as they are rewarded for these behaviors. The intentions of this project were to assess whether use of the smartphone app as an add-on to treatment as usual could increase treatment retention, increase the percentage of appointments that were kept, and if substance use could be reduced for patients using the app.
Patients were enrolled in the study on a rolling basis from Jan 25, 2019 to March 29, 2019 until the desired cohort group # was reached (n=108). The intervention period (period of time when patients actually used the DynamiCare app) lasted four months from the date of their enrollment.
Study Type : | Observational |
Actual Enrollment : | 108 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Prospective Cohort Study of Contingency Management Using A Smartphone Application in Patients With Substance Use Disorder |
Actual Study Start Date : | January 25, 2019 |
Actual Primary Completion Date : | July 29, 2019 |
Actual Study Completion Date : | July 29, 2019 |
Group/Cohort | Intervention/treatment |
---|---|
DynamiCare group
Patients at Morgan Street location of BrightView who were given the DynamiCare smartphone app.
|
Device: Smartphone app
Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment. |
Non-DynamiCare group
Patients at Colerain location of BrightView who were not given the DynamiCare smartphone app.
|
- Attendance [ Time Frame: 4 months ]The DynamiCare smart phone app was used to see whether the percentage of scheduled appointments could be increased by using the app. As measured by % of attendance of medical and clinical appointments compared to controls.
- Substance Use [ Time Frame: 4 months ]The DynamiCare smart phone app was used to see if use of the app could reduce substance use as measured by urine toxicology results. Measured percentage of patients using the app testing consistent only for prescribed substances in random clinical urine tests compared to controls.
- Retention [ Time Frame: 4 months ]The DynamiCare smart phone app was used to see if treatment retention could be increased when the app was added to treatment as usual. Measured as the percent of patients who are still active in the DynamiCare app and attending treatment sessions after 1, 2, 3, and 4 months compared to controls.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- >18 years old
- Substance use disorder (SUD) as a primary diagnosis
- Have and use an Android or iOS smartphone with acceptable capability
- Are willing to participate in home testing and use of the smartphone
- Speak and read the English language adequately to understand smartphone commands and responses
- Are willing to be randomly assigned to receive treatment with or without the smartphone app as an added feature.
Exclusion Criteria:
• N/A

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04162132
United States, Ohio | |
BrightView | |
Cincinnati, Ohio, United States, 45206 |
Principal Investigator: | Shawn Ryan, MD, MBA | President & CMO | |
Study Director: | Samin Rezania, PhD | Director of Clinical Research |
Documents provided by BrightView LLC:
Responsible Party: | BrightView LLC |
ClinicalTrials.gov Identifier: | NCT04162132 |
Other Study ID Numbers: |
7135-SRyan |
First Posted: | November 14, 2019 Key Record Dates |
Last Update Posted: | November 20, 2019 |
Last Verified: | November 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
contingency management smartphone app substance use disorder |
outpatient addiction treatment BrightView DynamiCare |
Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |